Literature DB >> 11150717

Cellular processing of (125)I- and (111)in-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells.

A Orlova1, A Bruskin, A Sjöström, H Lundqvist, L Gedda, V Tolmachev.   

Abstract

Low molecular weight of epidermal growth factor (EGF) enables better intratumoral penetration in comparison with larger targeting proteins, but the cellular retention of EGF-associated radioactivity is poor for directly iodinated EGF. An attempt was made to improve intracellular retention by the use of metal-diethylenetriaminepentaacetic acid or nonphenolic linker (N-succinimidyl-para-iodobenzoate) as labeling agents. The use of nonphenolic linker did not improve retention of the radioactivity in A431 carcinoma cell line. The use of the radiometal label provided an appreciable prolongation of radioactivity residence inside the cell.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11150717     DOI: 10.1016/s0969-8051(00)00148-7

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  3 in total

Review 1.  Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression.

Authors:  J Carlsson; Z P Ren; K Wester; A L Sundberg; N E Heldin; G Hesselager; M Persson; L Gedda; V Tolmachev; H Lundqvist; E Blomquist; M Nistér
Journal:  J Neurooncol       Date:  2006-03       Impact factor: 4.130

2.  Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence.

Authors:  Torun Engfeldt; Anna Orlova; Thuy Tran; Alexander Bruskin; Charles Widström; Amelie Eriksson Karlström; Vladimir Tolmachev
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-12-05       Impact factor: 9.236

3.  The influence of Bz-DOTA and CHX-A''-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy.

Authors:  Vladimir Tolmachev; Helena Wållberg; Karl Andersson; Anders Wennborg; Hans Lundqvist; Anna Orlova
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-09       Impact factor: 9.236

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.